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The HCV hypervariable region 1 (HVR1) of the main E2 envelope protein is critically important in HCV neutralization but
its extreme variability makes immune therapy and vaccine development particularly difficult. To explore the hypothesis that
HVR1 carries a common epitope susceptible of eliciting cross-reactive neutralizing and inhibitory antibodies, rabbits were
immunized with a series of synthetic HVR1 peptides. The anti-HVR1 produced were purified and characterized. Several lines
of evidence supported the working hypothesis: (1) although injected only once, a boosting effect from poorly homologous
peptides was observed; (2) purified rabbit IgG reacted with high affinity with immunizing peptides and cross-reacted with 16
of 17 unrelated HVR1 peptides; (3) antibodies appeared of restricted diversity irrespective of the linear HVR1 peptide
sequences; (4) anti-HVR1 peptides effectively captured HCV in 22 of 33 plasmas from random infected patients; (5) anti-HVR1
IgG blocked the binding of antibody-captured HCV to MOLT-4 cells. These findings suggest that with an appropriate HVR1
peptide immunization scheme, high titer, broadly cross-reactive, blocking antibodies to HCV can be produced. Antibodies to
the putative ubiquitous HVR1 epitope may have important clinical uses. © 1999 Academic Press
o
t
w
s
1
a
a
e
t
s
i
w
p
c
c
i
p
r
w
a
i
l
R
cINTRODUCTION
Hepatitis C virus infection is often persistent because of
he inability of the host to mount a sufficiently efficient
umoral and cellular immunity (Farci et al., 1992; Weiner et
l., 1995; Nelson et al., 1997). This phenomenon is essen-
ially related to the capacity of HCV to escape immune
ecognition by frequent mutations, particularly in the hyper-
ariable region of the main E2 envelope protein (HVR1)
Weiner et al., 1992; Kato et al., 1993). Random mutations
ause amino acid substitutions modifying linear and, pos-
ibly, conformational epitopes. Mutants capable of escap-
ng from neutralizing antibodies produced by the patients
ake immune therapy and vaccine development particu-
arly difficult. The HVR1 domain contains two overlaping
inear B-cell epitopes in the C-terminus part that are well
xposed at the outside of the virus and appear to be
tructurally flexible (Kato et al., 1994; Taniguchi et al., 1993).
he relatively low level of viremia observed in chronically
nfected patients may play a role in the poor level of im-
une response to HCV antigens. Several studies con-
ucted in chronically infected chimpanzees showed that
he immune response was unable to protect the animals
gainst reinfection by a different, or the same, viral strain
Farci et al., 1992; Kato et al., 1994; Taniguchi et al., 1993;
kamoto et al., 1992; Farci et al., 1994).
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396However, several investigators, including our group,
bserved that the antibodies present in a large propor-
ion of infected patients had significant cross-reactivity
ith apparently unrelated HVR1 sequences presented as
ynthetic peptides (Rosa et al., 1996; van Doorn et al.,
995). The observations (1) that three conserved amino
cid were present at position 2 (threonine), 23 (glycine),
nd 26 (asparagine) of the HVR1 sequence; (2) that the
xtent of amino acid substitution of the C-terminus por-
ion of HVR1 was limited; and (3) that HVR1 was a main
ite for neutralization playing an important functional role
n viral attachment to target cells suggested that HVR1
as likely to present common motifs recognisable by
utative target cell receptors.
The present study aimed at gathering evidence that a
ommon epitope was present in the HVR1 region that
ould be used to develop highly cross-reactive antibod-
es with sufficient functional potency for diagnostic and,
otentially, clinical usage. High titers anti-HVR1 raised in
abbits serially immunized with different HVR1 peptides
ere characterized for affinity, specificity, and cross-re-
ctivity for HVR1. The ability of these polyclonal antibod-
es to capture viral particles and to block HCV binding to
ymphocytic target cells was studied.
RESULTS
eactivity of rabbit sera to HVR1 immunizing peptides
Two rabbits were immunized with six individual KLH-
onjugated HVR1 peptides (Table 1A). These peptides
ad between 43 and 71% homology and were selected
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397ANTIBODY TO HVR1ecause of a relatively high frequency of cross-reactivity
ith a previously described panel of HCV-infected pa-
ient sera (Jackson et al., 1997). The rabbit antibody
esponse to immunizing HVR1 peptides was tested by
LISA. In rabbit 1, the antibody response to the first three
mmunizing peptides (MH2, MH3, and MH4) was high
nd persistent. The antibody response to the next two
eptides (W1 and L1.1) was low and was undetectable
ith the last immunizing peptide (LV) (Fig. 1a). In rabbit 2,
ntibody response to all immunizing HVR1 peptides was
bserved. One week after day 45, when peptide MH4
as injected, a high anti-MH4 response was observed
nd, when peptide MH3 was injected (day 60), a high
evel of reactivity to MH3 was already present in the
abbit serum. In addition, at day 75, when peptide MH2
T
Sequences of HCV P
Peptidesa Seq
A C K G L N G L
M H 3 - Y - - T T -
M H 4 - S - - S S -
L 1 1 C T T S - - A S -
W 1 - D T A - - A - -
L V - N T H - I A S -
B
M H 1 - N R - G - -
M H 5 - N R F A - M
D H 1 - G - V A - -
D H 2 - G M F T - -
U S 1 - S - F V - -
L B 1 - - T S - F A S -
L B 2 - - T S - F T S -
W 2 - D T S A - V - -
F R 1 - N T Y - - T A -
F R 2 - I V N R R T S F
L 1 2 - - T R - - A S -
S 6 5 - R R V A S F
S 6 6 - L - I A S F
S 8 2 - T - F S N -
S 8 5 - A A - A S -
S 8 - T - F S K H
S 9 0 - A A - A N S
C
S 5 A T R K T S E R S
S 6 P K A R Q P
S 8 S R P S W G P T D
S 1 9 S G H R M A
S 3 4 D C F R K H P E A
S 9 1 C G T Y V T G
a Synthetic peptide sequences (using one-letter codes) from HVR1 an
f HCV isolates used for immunization. (B) Peptides of the HVR1 C-term
f antibodies form the immunized rabbits. HVR1 peptides are aligned u
ore region of the same HCV isolate, S19 from the E1 region, S34 from t
sed for testing the specificity of antibodies from the immunized rabbits
oupling to the BSA or KLH carriers.as injected, maximum anti-MH2 reactivity was already Heached. These results suggest that some peptides had
clear boosting effect on the production of highly cross-
eactive antibodies elicited by a previously injected pep-
ide, although the linear sequences were poorly homol-
gous (Fig. 1b).
pecificity of individual rabbit sera against HVR1
eptides
As shown in Fig. 2, rabbit 1 and 2 sera reacted with
everal but often different, unselected HVR1 peptides
erived from unrelated HCV-infected patients (Table 1).
eactivity against all studied HVR1 peptides except pep-
ide W2 was observed with either or both rabbit 1 or 2
era. To obtain an antibody with the largest possible
s Used in the Study
Region
G P K Q K I H V R 1
- - R - Q -
- - - - Q -
- A R - H
- - - - T
- - A - -
- - - - - -
- A R - - -
- S Q - - L
- A Q - - L
- - S - R -
- - S - -
- - S - -
-
- - S - Q
- - S - R
- A R - H
- S A - - -
- - - - N -
- S Q - - V
- - Q - - N
- S Q - - V
- - Q - - V
G R R Q P I C C O R E
A W A Q P G -
R S R N L G -
M M N W S P - E 1
K C G S G P - E 2
G R T V H R H V R 1 N
HVR1 regions of HCV. (A) Peptides derived from the HVR1 C-terminus
erived from different HCV isolates used for testing the cross-reactivity
2 as lead sequence. (C) Peptides S5, S6, and S8 are derived from the
egion (not HVR1), S91 from the HVR1 N-terminus. These peptides were
peptide sequences a N- or C-terminal cysteine was added to facilitateABLE 1
eptide
uence
F D L
- - P
- T P
- N S
- N -
- A F
- N F
- S -
- K M
- N Q
- S P
- K F
- R -
L S P
L S P
- N -
- T S
L I R
L I R
- N -
- L S
N N M
L S -
Q P R
E G R
P R R
W D M
T Y T
G A S
d non-
inus d
sing MH
he E2 r
. To allVR1 cross-reactivity, sera collected 90 days post first
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398 SHANG, ZHAI, AND ALLAINmmunization from rabbits 1 and 2 were mixed and pu-
ified IgG was used as a single reagent in further studies
rabbit IgG).
haracterization of rabbit anti-HVR1 IgG
Rabbit IgG concentration was 4.4 mg/ml. Affinity con-
tants against HVR1 representative immunizing peptides
H2, MH3, and LV determined by surface plasmon res-
nance were Kds of 2.15 3 10
28, 6.98 3 1027, and 4.79 3
026, respectively (Table 2).
Rabbit IgG titers against HVR1 immunizing peptides,
nselected HVR1 peptides, and HCV core, E1, and E2
other than C-terminus HVR1) peptides were determined
y limiting dilution tested by ELISA. As shown in Fig. 3,
abbit IgG reacted with all immunizing peptides and
ross-reacted with 16 of 17 unrelated C-terminus HVR1
eptides, with titers ranging between 1:1000 and
:100,000. No reactivity was observed with five non-HVR1
eptides shown in Table 1c [S5, S6, and S8 (core); S19
FIG. 1. (a) Immune response of rabbit 1 to 6 HVR1 peptides ex-
ressed as sample to cutoff (S/CO) ratio obtained with individual
eptide ELISAs. Each rabbit was immunized with a single intradermal
njection of 400 mg of KLH-conjugated HVR1 peptides with Freud’s
djuvant (Table 1). Serum samples were taken at 15-day intervals
tarting at day 45, prior to injection of the third peptide. The mean of 10
eplicates of preimmunization plasma plus 4 SD defined the cutoff.
eptide codes are shown in the box; peptide sequences are provided
n Table 2. (b) Immune response of rabbit 2 to six HVR1 peptides as in
a) but injected at 2-week intervals in the reverse order. Preimmuniza-
ion plasma from rabbit 2 was used as a negative control to define the
utoff as in (a).E1); S34 (E2); and S91 (HVR1 N-terminal peptide)]. gTo examine the potential clonal restriction of the anti-
VR1 reactivity we immunopurified rabbit IgG with two
mmobilized immunizing peptides (MH3 and W1) and
hree cross-reactive peptides (S90, LB1, and DH1) and
ested the reactivity of these peptide-immunopurified an-
ibodies against our panel of HVR1 peptides and the core
5 peptide as negative control. With each antibody, 12–15
eptides showed a reactivity above the cutoff level
mean of 24 replicate of negative controls plus 4 SD).
welve peptides reacted with either all (MH3, MH4, W1,
66, MH2, MH1) or 4 immunopurified antibodies (S90.
1.1, LV, US1, FR2, FR1) with sample to cutoff ratios rang-
ng from 1 to 19. When the sequences of these 21 pep-
ides were compared to the sequences of the 11 less or
ot (W2, S82, S85, S87) reactive peptides, no relationship
etween the linear peptide sequence and ELISA reactiv-
ty was found. Phylogenetic analysis of the 23 HVR1
eptides distributed into two main branches (data not
hown). Six of the 12 highly reactive peptides were lo-
ated in each of these two branches.
To examine the potential importance of peptide con-
ormation in their interaction with rabbit IgG, the 6 immu-
izing peptides and 11 unrelated peptides (Table 1) were
enatured by heating at 100°C for 10 min and used for
oating microtiter plates in parallel with untreated pep-
ides. By ELISA, the reactivity of immunizing treated pep-
ides was decreased (mean decrease 17%, range
–43%). In contrast, reactivity with other peptides was
nchanged (8 peptides), decreased (5 peptides, range
–29% decrease), or increased (4 peptides, range 14–
2%).
CV RNA capture with rabbit anti-HVR1 IgG
Since rabbit IgG had a high titer, high affinity, and
road HVR1 cross-reactivity, we next assessed the ca-
acity of rabbit IgG to capture HCV in plasma, presum-
bly through the HVR1 C-terminus epitope. HCV RNA
rom 22 of 34 random HCV RNA-positive plasma samples
65%) was detected by rabbit IgG capture assay. Repre-
entative examples are shown in Fig. 4. In all cases the
lasma supernatant after capture was positive for HCV
NA, suggesting that, when positive, only part of the
irculating HCV population was detected with the rabbit
gG-based capture system. The same experiment per-
ormed with preimmunisation rabbit antibody mixture
as consistently negative.
In order to explore the potential effect of viral concen-
ration on the anti-HVR1 viral capture system, we quan-
ified by limiting dilution of HCV RNA levels of 23 of 34
CV RNA-positive samples and examined the distribu-
ion of positive and negative capture results. As shown in
able 3, the distribution of anti-HVR1 capture positive
nd negative samples was not significantly influenced by
CV viremia levels within a range of 3 3 103 to 5.2 3 106eq/mL.
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399ANTIBODY TO HVR1The potential impact of HCV genotype on HCV capture
y rabbit antibody was also explored. Twenty-eight avail-
ble samples were typed with the Innogenetics assay
Petrik et al., 1997). Seven were genotype 1, 5 1a, 9 1b, 2
enotype 2, and 2 2a, and 3 genotype 3a. The rabbit IgG
apture assay was positive in 17 of 21 samples, with
enotype 1, 1/4 with genotype 2, and 2/3 with genotype 3.
he difference in capture positivity between genotypes
as not significant.
To determine the mechanisms underlying HCV cap-
ure with rabbit IgG, a series of experiments was con-
ucted. Sera from two random capture-positive and two
apture-negative sera were submitted to protein G chro-
atography. Flow-through and eluted fractions were
ested for HCV RNA by both rabbit IgG capture and
tandard HCV RNA detection assay. The standard assay
etected HCV RNA in both fractions of all four samples,
uggesting that all samples contained free and com-
FIG. 2. Cross-reactivity of plasma from rabbit 1 (black columns) and
eptides expressed as sample/cutoff ratio. Sequences are shown in
orresponding preimmunization rabbit plasma. Only peptide W2 did no
TABLE 2
Affinity Constant (Kd) of Rabbit IgG to HCV HVR1 Peptides
eptide Kdiss (S
21 3 1023) Kass (m
21S21 3 104) Kd (M)
MH2 1.942 0.901 2.15 3 1028
MH3 7.189 1.031 6.98 3 1027
26s
LV 5.345 0.111 4.76 3 10lexed HCV. The capture assay detected HCV RNA in the
low-through and eluted fractions of capture-positive
amples (data not shown). These results suggested that
abbit IgG capture is limited not by the free or complexed
tate of HCV but by the presentation of the HVR1 epitope.
his conclusion was further supported by comparing
vailable HVR1 sequences from three patients: two pos-
tive and one negative with the capture assay. The two
aptured viruses had HVR1 sequences 73 and 66% ho-
ologous to the consensus sequence of the six peptides
sed for rabbit immunization, while the noncaptured vi-
us had 33% homology. Since some of the HCV captured
n the eluted fraction was likely to have dissociated
uring the elution process, we could not determine
hether complexed virus was captured. We then ultra-
entrifuged at 35,000 g for 4 h two capture-positive sera
nd tested HCV RNA by capture and standard assays in
he pellet containing mostly complexed virus and the top
raction containing mostly free virus (Hijikata et al., 1993).
CV RNA was detected by capture assay in both pellet
nd top fractions of the ultracentrifugation tube, suggest-
ng that free and complexed HCV were detectable by
abbit IgG capture. However, when each of these frac-
ions was submitted to protein G chromatography as
escribed above, a strong HCV RNA signal with standard
T–PCR was observed with the top fraction but a weak
(gray columns) with 11 HVR1 peptides different from the immunizing
. The cutoff of the peptide ELISA was as defined in Fig. 1, using the
-react with the plasma of either rabbit.rabbit 2
Table 1ignal with the bottom fraction from both rabbit capture-
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400 SHANG, ZHAI, AND ALLAINositive and -negative samples, suggesting that either
ome complexed HCV easily dissociated or that the
ellet contained small amounts of contaminating free
CV.
FIG. 3. Titration of rabbit IgG reactivity with six immunizing HVR1 pept
eptides by ELISA. The titer was calculated as the dilution correspond
negative reaction. Only peptide W2, as in Fig. 2, did not cross-react
FIG. 4. HCV RNA detection by capture with anti-HVR1 rabbit IgG
ound to magnetic microparticles. Representative samples were tested
s described under Materials and Methods. R-IgG, rabbit anti-HVR1
gG used for HCV capture; PIR-IgG, preimmunization rabbit IgG used as
egative control. Numbers correspond to the patients’ serum sample
odes or negative sample (N) controls. The top line shows ethidium
romide-visualized amplicons obtained by nested RT–PCR using core
egion primers after RNA extraction from washed microparticles. The
ottom line shows HCV amplicons obtained after RNA extraction from
erum supernatants after HCV capture with microparticles which were
sed as positive controls. Samples from patients 1–3, 5, and 6 are
apture positive; patient 4 and 7 plasmas are capture negative.
Clocking of viral attachment by rabbit anti-HVR1 IgG
The ability of rabbit IgG to block HCV binding to sus-
eptible cells was tested using MOLT-4 cells as target.
lasmas from three patients whose virus was captured
y rabbit IgG and two who did not were used as source
f HCV. As shown in Fig. 5, HCV binding to MOLT-4 cells
as blocked in a dose-related fashion by rabbit IgG only
ith the three plasmas positive in the HCV capture as-
ay. Partial blocking was observed with 0.5 mg/ml of
abbit IgG and no cell-associated HCV RNA was detect-
ble after incubation of patients plasmas with 5 mg/ml of
ntibody. Rabbit IgG did not affect HCV binding to
OLT-4 cells when HCV RNA containing plasmas, neg-
tive with the HCV RNA capture assay, were used as
ource of HCV.
DISCUSSION
Mechanisms of HCV persistence include the ability of
he virus to mutate, particularly in the neutralizing HVR1
H2–LV, first six bars from left) or cross-reactivity with 17 nonimmunizing
xtinction of signal, using preimmunization rabbit IgG mixture to define
bbit IgG.
TABLE 3
Influence of Viral Concentration on HCV Capture
HCV concentration
(geq/ml) ,104 104–105 105–106 .106 Total (%)
o. of samples 3 11 2 7 23
apture positive 2 8 1 4 15 (65)ides (M
ing to eapture negative 1 3 1 3 8 (35)
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401ANTIBODY TO HVR1egion of E2, the relatively low immune reactivity of HCV
roteins (in part related to the low level of viremia), the
igh specificity of antibodies to HVR1 which does not
ross-neutralize emerging variants in patient quasispe-
ies, and the insufficiently effective cytotoxic T-lympho-
yte response to viral epitopes (Okamoto et al., 1992;
ackson et al., 1997; Zibert et al., 1997; Shimizu et al.,
994; Chang et al., 1997). Attempts at protecting chim-
anzees from HCV infection by inducing an immune
esponses to E2, and in particular to HVR1 epitopes,
ave been shown to be poorly effective, to a large extent
n relation with the restricted specificity of the antibodies
roduced (Okamoto et al., 1992; Farci et al., 1994; Rosa et
l., 1996; van Doorn et al., 1995). One critical limitation in
he development of HCV vaccines and of passive immu-
otherapy has been the difficulty of eliciting cross-reac-
ive antibodies. However, a number of investigators have
ointed out that HVR1 was directly involved in the neu-
ralization of HCV, essentially by blocking viral attach-
ent to target cells (Okamoto et al., 1992; Rosa et al.,
996; Pileri et al., 1998; Zibert et al., 1995; Shimizu et al.,
996). Preliminary data obtained in our laboratory and by
thers suggested that HVR1, although highly variable,
etained three conserved amino acids and had substitu-
ion constraints in the mutation observed in the C-termi-
us part of HVR1 which is the site of neutralizing epitope
Rosa et al., 1996; van Doorn et al., 1995; Jackson et al.,
997). We therefore formulated the hypothesis that a
ommon, ubiquitous, HVR1 epitope might exist, related
o the conserved amino acid and presumably largely
onformational. To test this hypothesis, we designed
mmunization schemes of rabbits involving known C-
FIG. 5. Effect of preincubation of HCV RNA-positive plasmas either
nti-HVR1 capture positive (K, L1A4, L3A1) or negative (D, C) with four
oncentrations of rabbit IgG (1–4 or 5 mg–5 ng/ml) on the HCV binding
o MOLT-4 cells. The figure is representative of experiments performed
n triplicate. Negative controls were cells in plasma without HCV;
ositive controls were supernatants of the incubation mixture. In all
hree HCV capture-positive samples, 5 mg/ml of rabbit IgG totally
locked HCV binding; partial blocking is obtained with 0.5 mg/ml. No
locking is observed with two HCV capture-negative samples.erminus sequences of HVR1 derived from patients who 3eacted strongly against their own HVR1 epitope and
hose sequence was frequently recognized by sera from
nrelated patient infected by largely divergent virus. The
eactivity of two rabbits immunized with the same six
VR1 peptides injected at 2-week intervals in reverse
rder elicited antibodies with different specificies and
evels of reactivity (Fig. 1). The sequence of immunization
f rabbit 2 was considerably more effective and provided
ome indication that a peptide could boost antibody to
nother peptide less than 50% homologous. In addition,
erum from each immunized rabbit reacted not only with
mmunizing peptides but also against unrelated peptides
ith limited sequence homology (Fig. 2). By mixing sera
rom the two rabbits an IgG preparation with larger
ross-reactivity was obtained. These data suggest that
n HVR1 epitope, unrelated to the linear sequence of the
VR1 peptides except for the G and Q at positions 23
nd 26, was elicited by the immunization scheme. Rabbit
gG or individual rabbit sera reacted with HVR1 se-
uences less than 40% homologous to any of the immu-
izing peptides, suggesting that the binding epitope is
ikely to be, at least in part, conformational. These results
ere further supported by the cross-reactivity of peptide-
mmunopurified specific anti-HVR1 rabbit IgG with unre-
ated HVR1 peptides. Whether antibody was purified with
mmunizing or cross-reactive peptides, the same group
f HVR1 peptides was recognized, and this recognition
as independent of the peptide linear sequences. Our
ata strongly suggest that rabbit antibody is of restricted
pecificity and directed against a nonlinear epitope.
ome of our data, however, are at variance with recently
eported results by Esumi et al. (1998), who immunized
ice with peptides twice as long as ours (30 aa), includ-
ng the N-terminus part of HVR1. They did not observe a
ood immune response against the C-terminus se-
uences of HVR1. This difference might be related to the
act that longer peptides might conform differently from
horter ones, possibly masking critical epitopes.
Rabbit IgG has not only broad cross-reactivity with a
arge panel of peptides unrelated to the immunizing
eptides but also high titers (Fig. 3) and high affinity
ogether with high specificity for HVR1 (Table 2). We
herefore evaluated the ability of this antibody to interact
ith HCV viral particles. The broad cross-reactivity and
igh affinity of rabbit IgG observed with HVR1 peptides
as also found with whole virus as target. Sixty-five
ercent of HCV from random infected UK blood donors
Fig. 4) were captured by immobilized rabbit IgG. This
ercentage is considerably higher than the 20% (1 of 5
atients) capture observed by Esumi et al. (1998) using
n immunoprecipitation method and antibodies obtained
y immunization with peptides of considerably less se-
uence diversity than ours. Viral HVR1 recognition by
abbit IgG was independent of viral concentration (Table
) and HCV genotypes, at least with genotypes 1, 2, and
, the most prevalent in the UK. However, limited se-
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402 SHANG, ZHAI, AND ALLAINuence data on captured and noncaptured HCV suggest
hat HVR1 linear sequences may have some relevance to
he absence of capture of HCV in 35% of patient plasmas
Esumi et al., 1998). This conclusion was further sup-
orted by experiments comparing rabbit IgG binding to
ative or denatured HVR1 peptides. After boiling, the
eactivity of immunizing peptides was partially de-
reased, but cross-reactivity with random peptide was
iversely affected. Our result suggest that rabbit IgG
ecognizes an epitope partly defined by the linear se-
uence (presumably the conserved G and Q in positions
3 and 26, respectively), partly by conformation.
An alternate explanation for the lack of capture of HCV
rom some patients is that only free virus may be avail-
ble for antibody capture. It has been shown by several
nvestigators that HCV circulate in plasma in either an-
ibody-complexed or free particle forms (Hijikata et al.,
993; Choo et al., 1995; Aiyama et al., 1996). It was
herefore possible that only viruses with a sufficiently
arge proportion of free HCV were detectable by capture.
irst, the free protein G column separated HCV present
n the follow-through fraction from a capture-negative
lasma was not captured by the anti-HVR1 rabbit IgG,
lthough HCV RNA was present. Second, experiments
esigned to determine whether IgG-complexed HCV was
lso captured were not totally conclusive since elution
rom protein G may have dissociated some virus and the
ltracentrifuged pellet of HCV-infected plasma appeared
ontaminated with free virus. However, it seems likely
hat rabbit IgG can capture complexed HCV either by
ecognition of a different E2 epitope than that recognized
y the patient antibodies or by displacement of the pa-
ient antibodies with antibodies of higher affinity. The
atter hypothesis is supported by previous studies of
nti-HVR1 in HCV-infected patients which showed that
ntibodies are of low titer (Rosa et al., 1996; Jackson et
l., 1997) and presumably low affinity. In addition, three
nti-HVR1 single chain Fv monoclonal antibodies ob-
ained by phage display technology in our laboratory
ere of extremely restricted specificity and low affinity
unpublished data). In their system, Esumi et al. (1998)
ound an apparently complete immunoprecipitation of
CV from the patient whose sequences were used to
erive immunizing peptides. This result only indicates
hat all detectable free virus was complexed with mouse
VR1 antibodies, not whether they recognized com-
lexed viruses.
Finally, we explored the functional potential of the
abbit polyclonal anti-HVR1 by assessing its capacity to
lock HCV binding to susceptible cells. Several previous
tudies indicated that blocking viral attachment to target
ells indicated neutralizing activity (Rosa et al., 1996;
ibert et al., 1995; Shimizu et al., 1996). Rabbit IgG
locked HCV binding to MOLT-4 cells in a dose-depen-
ent fashion but only virus in plasma from patients pos-tive with the IgG HCV RNA capture assay. These results ire consistent with a critical role played by HVR1 in the
CV–cell interaction (Rosa et al., 1996; Pileri et al., 1998).
n addition, total blocking of HCV binding was consis-
ently achieved with a concentration of 5 mg/ml of rabbit
gG. A pool of IgG from high anti-HCV-titer-infected pa-
ients blocked HCV binding to the MOLT-4 cell line at an
dentical concentration. These results indicate that anti-
odies to HVR1 raised in rabbits have the potential to
lock the binding of a broad spectrum of HCV strains to
usceptible cells. However, blocking viral attachment is
ot synonymous with neutralization, which requires a
ulture system to be evaluated. Our results also suggest
hat antibodies against a widely ubiquitous HVR1 epitope
an be produced and that appropriate HVR1 antigens
njected in an appropriate fashion may elicit broadly
ross-reactive, possibly protective, antibodies.
MATERIALS AND METHODS
lasma
Samples of HCV-infected plasma or serum were ob-
ained from prospective blood donors presenting at the
ast Anglian Blood Centre, or candidates for orthotopic
iver transplantation, or asymptomatic HCV carriers re-
erred to the consultant hepatologist at Addenbrooke’s
ospital (Cambridge, UK). HCV infection was shown by
he presence of antibodies using commercial HCV
creening (HCV-EIA, Abbott Laboratories) and confirma-
ory assays (RIBA 2 Ortho Diagnostics). All were positive
or HCV RNA detected by nested polymerase chain re-
ction (PCR) using a previously described method (Petrik
t al., 1997). HCV RNA was quantified as described
Lawal et al., 1997).
Peptides. A series of peptides ranging in size from 16
o 19 residues corresponding to the sequence of hyper-
ariable region 1 and other regions of HCV structural
roteins were synthesized commercially by either Cam-
ridge Research Biochemicals Ltd. or by Severn Biotech
td. Peptides were obtained at a purity greater than 85%,
sed without further purification, were dissolved to a
oncentration of 4 mg/ml in dimethyl sulfoxide/H2O (1:24,
/v) and stored at 235°C. The sequences of peptides
sed for immunizing and testing antibody cross-reactivity
re shown in Table 1.
Generation and purification of the immune sera. Six
eptides, MH2, MH3, MH4, L1.1, W1, and LV (Table 1A),
ere conjugated to keyhole limpet hemocyanin (KLH)
Sigma) by 3-maleimidobenzoic acid N-hydroxysuccinim-
de ester (MBS) (Sigma Chemical CO) coupling (Harlow
nd Lane, 1988a). Immune sera were generated by six
equential intradermal multiple site injections of the con-
ugated peptide in rabbits (400 mg) in Freund’s adjuvant
1, 15, 30, 45, 60, and 75 days). Rabbit 1 was injected with
onjugated peptide MH2 at day 1 and subsequently
njected with the other five peptides at a 2-week interval
n the sequence: MH3, MH4, L1.1, W1 and LV. Rabbit 2
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403ANTIBODY TO HVR1as injected according to the reverse sequence of con-
ugated peptides (LV at day 1, W1, L1.1, MH4, MH3, and
H2). Blood samples were drawn from each rabbit (pre-
mmunization, 45, 60, 75, and 90 days after initial injec-
ion of conjugated peptide). Sera from rabbits 1 and 2 at
ach time point were tested for reactivity with each
mmunizing peptide by ELISA. Sera at time points before
nd 90 days after injection from each rabbit were mixed,
nd the mixture was purified with a HiTrap Protein A
olumn according to the protocol of the manufacturer
Pharmacia Biotech). The purified immune serum was
esignated rabbit IgG. The preimmunization IgG was
sed as control.
For some experiments, rabbit IgGs were further immu-
opurified using immobilized HVR1 peptides as ligands.
VR1 peptides were cross-linked through the added
-terminal cysteine to thiopropyl Sepharose 6B gels ac-
ording to the protocol of the manufacturer (Pharmacia
iotech). Five 1.2-ml HVR1 peptide (MH3, LB.1, W1, S90,
nd DH1) affinity chromatography columns were pre-
ared and used to purify antibodies against HVR1 from
abbit IgG. Each of the immobilized peptide columns was
oaded with 1 ml of rabbit IgG (10 mg/ml); after washing
he column with 10 ml binding buffer (20 mM sodium
hosphate, pH 7.0), bound IgG was eluted with 0.1 M
itric acid, pH 3.5. The collected fractions were neutral-
zed with 1 M Tris–HCL, pH 9.0. The concentration of
rotein in each fraction was measured using a UV-vis
pectrophotometer (Shimadzu Corp., Kyoto, Japan) and
he three fractions with highest absorbance were pooled.
LISA was performed using a concentration of protein
djusted to 6.5 mg/ml.
Affinity of rabbit antibody. The affinity of rabbit IgG
gainst HCV HVR1 peptides was determined by surface
lasmon resonance using the IASYS optical biosensor
Affinity Sensor, Cambridge UK). Peptides MH2, MH3,
nd LV (100 mg/ml in 10 mM sodium acetate buffer, pH
.0) were immobilized on the surface of carboxymethyl
extran cuvettes using DEC/NHS chemistry according to
he manufacturer’s instructions. The remaining activated
ites were blocked with 1 M ethanolamine, pH 8.5. Dif-
erent concentrations of rabbit IgG in PBS were then
dded to the cuvettes. Association was measured for 5
in and dissociation for 3 min. Using the Fastfit program
Affinity Sensor), the apparent association (Kon) and dis-
ociation (Koff) rates were calculated for the binding of
abbit IgG with each peptide. The Kd was then calculated
s Koff/Kon (Neri et al., 1996).
Peptide enzyme immunosorbant assay (peptide
LISA). The reactivity of rabbit sera and rabbit IgG with
arious HCV peptides was determined by ELISA as fol-
ows: the wells of a 96-well microtiter plate (Nunc-im-
uno plate, maxisorp, Life Technologies) were coated
ith 100 ml per well of a 5.0 mg/ml solution of peptides
nd incubated at 4°C for 16 h. The wells were washedhree times with PBS and incubated for 60 min at room cemperature (22°C) with 3% BSA in PBS. Serial dilutions
100 ml/well) of rabbit sera or rabbit IgG in PBS-B buffer
4% BSA in PBS, w/v) were incubated for 60 min at 37°C
nd, subsequently, for 60 min at 37°C with a 100ml/well
olution of goat anti-rabbit IgG conjugate to alkaline
hosphatase (Sigma) used at a 5000-fold dilution in
BS-B. Wells were washed five times with PBS-T (0.1%
ween 20 in PBS, v/v). The alkaline phosphatase reaction
as visualized using the p-nitrophenyl phosphate
pNPP) solution in 0.1 M glycine buffer (1 mg/ml) (200
l/ml). After 30 min incubation at 22°C the reaction was
topped by the addition of 50 ml of 3 N sodium hydroxide
o each well, and the absorbance was measured at 405
m on a Titertech 96-well plate reader. The cutoff for
ach plate was calculated as the mean plus four times
he standard deviation for the absorbances of 10 aliquots
f preimmunization rabbit sera or IgG. In some experi-
ents, peptides were denatured by heating at 100°C for
0 min and used to coat microtiter plates. Peptide ELISA
as then performed as described.
HCV RNA capture assay. Rabbit IgG at a concentration
f 1 mg/ml was labeled with biotinamidocaprote n-hy-
roxysuccininide ester as described (Harlow and Lane,
998b). Rabbit IgG labeled with biotin was bound to
treptavidin-coated paramagnetic particles (SA-PMPs)
ccording to the manufacturer’s protocol (Promega). Af-
er washing three times, the particles were resuspended
n 1 ml of PBS. SA-PMPs-IgG (cross-linked with the rabbit
gG) and SA-PMPs-pIgG (cross-linked with preimmuniza-
ion rabbit IgG) were used for HCV capture assay as
ollows: 80 ml of the SA-PMPs-IgG or SA-PMPs-pIgG
uspension was mixed with 150 ml of each serum or
lasma (confirmed HCV RNA positive) with 1 ml of PBS in
1.5-ml Eppendorf tube. After 2 h incubation at 37°C with
otation, the particles were concentrated with a magnetic
tand (Promega). The supernatant was pipetted and
sed as a positive control of RT–PCR. After washing
hree times with 1.4 ml of PBS, an aliquot of the last wash
as kept and the particles, resuspended in 150 ml PBS,
ere used for the extraction of HCV RNA. Preliminary
tudies performed in duplicate with three samples con-
aining 1–2.5 3 106 genome equivalents of HCV RNA
howed that after three washes in PBS, HCV RNA which
as present in the initial microparticle supernatant after
apture was no longer detectable. HCV RNA detection
as performed with nested RT–PCR. In all experiments,
icroparticles coated with preimmunization rabbit anti-
ody was used as negative control and patient plasma
s positive control.
HCV RNA detection. Viral RNA was extracted from
ither 100 ml cell suspension or 100 SV-PMPs-IgG sus-
ension using RNAzol B RNA isolation solvent according
o the protocol of the manufacturer (AMS Biotechnology,
urope). The extracted RNA was resuspended in 15 ml
EPC-treated water, and 5 ml RNA was transcribed into
DNA using 30 pmol of primer 59-GATGTACCCCATGAG-
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404 SHANG, ZHAI, AND ALLAINTCGG-39 (anti-sense primer, 732–751) by superreverse
ranscriptase (21 u) (HT Biotechnology Ltd., UK) in a
eaction of 20 ml. Two rounds of PCR were performed
sing 2 ml of the respective cDNA mixtures in a total of
0 ml using Ampli Taq DNA polymerase (2 ml) and 30
mol primers. In the first round of PCR and RT primer and
he sense primer 59-GCGCGAIAGGAAGACTTCG-39 (481–
99) were used. The second round of PCR was per-
ormed with primer 59-CGTGGAAGGCGACAACCTAT-39
515–535) and primer 59-CGCATGTTAGGGTATCGAT-39
706–725). The Southern blotting analysis was carried
ut with probe 59-ATGGGCTGGGCAGGATGGCTC-39
661–632) with 59 digoxigenin-labeled using a DIG
hemiluminescent kit (Boehringer Mannheim) according
o the manufacturer’s instructions.
Cell binding and blocking assays. The human T-cell
ine MOLT-4 was used in the binding and blocking as-
ays. Cells were maintained in RPMI 1640 medium with
0% heat-inactivated fetal calf serum. To determine cell
bsorption efficiency of circulating HCV, plasmas MH,
1A4, L3A1, K, C, and D were serially diluted in 10-fold
ncrements in RPMI 1640 medium, and 100 ml of each
ilution was added to 0.5 ml of a suspension of 5 3 105
OLT-4 cells. After incubation for 2 h at 37°C, cells were
ashed twice with 10 ml PBS and tested for cell-ad-
orbed HCV RNA by RT–PCR using nested primers
hich detected the core region of HCV genome. This
eries of experiments provided for each sample a HCV
NA absorption titer which was subsequently used to
djust the virus concentration in blocking experiments.
he blocking assay was as follows: a 100-ml sample of
ach target virus (at the adjusted dilution of 1022 for
ample L3A1;1021 for L1A4, C, and D; undiluted for MH
nd K) was incubated overnight at 4°C with an equal
olume of either rabbit IgG (5 mg/ml, 0.5 mg/ml, 50 ng/ml,
nd 5 ng/ml) or control preimmunization IgG. Each mix-
ure was added to 0.5 ml of a 5 3 105 MOLT-4 cell
uspension and incubated for 2 h at 37°C. After washing
wice with 10 ml of PBS, RNA was extracted and HCV
NA in cell pellets and supernatants was detected by
T–PCR. After the first wash with PBS, HCV RNA was no
onger detectable. All experiments were carried out in
uplicate. The positive control was patient plasma su-
ernatant after cell absorption and the negative control
as plasma of a HCV RNA-negative blood donor.
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